{
  "case_id": "MN22-38337",
  "year": 2022,
  "patient_info": {
    "age_range": "41 to 50",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [
    "symptom flare-up"
  ],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Anti-inflammatories",
  "treatments_requested": [
    {
      "name": "Rituximab",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "500 mg once a week for four weeks"
    }
  ],
  "treatments_tried_but_failed": [
    {
      "name": "Mycophenolate Mofetil",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Azathioprine",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Methotrexate",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Infliximab",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Hydroxychloroquine",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [
    {
      "name": "Rituximab",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "FDA supports use of biosimilars"
    }
  ],
  "is_denial_upheld": true,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": null,
  "guidelines_not_support": null,
  "guidelines_details": "FDA supports treatment with biosimilar products.",
  "soc_support": null,
  "soc_not_support": null,
  "soc_details": null,
  "study_support": null,
  "study_details": [],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": true,
  "rationale": "The requested Rituxan is not medically necessary as there is no documented trial or failure of a Rituxan biosimilar product, which is supported by FDA guidelines.",
  "reviewer_credentials": "Board certified in internal medicine with subspecialty certification in rheumatology, actively practicing, expert in treatment of systemic lupus erythematosus."
}